OP 1.1

Oral mucous membranes can be affected by various viruses, each causing distinct clinical and pathological presentations.
Herpesviruses: This extensive family contains viruses with a DNA core, surrounded by a capsid and an envelope. Seven types are pathogenic in humans, with six affecting the head and neck area.

Herpes Simplex Virus (HSV) infections result in widespread vesicular eruptions on the skin and mucosa, existing in two forms:
- Systemic or Primary
- Localized or Secondary
Both forms typically resolve without treatment, though recurrent outbreaks of the secondary form are common due to latent virus sequestering in ganglionic tissue.
Treatment usually focuses on control rather than cure.

Transmission: Infection in seronegative individuals typically occurs through physical contact with an infected individual.
The virus binds to the cell epithelium via heparan sulfate, activating specific genes (immediate early, early, and late genes) involved in viral replication and structural protein formation.
Infection Spread: Lacks significant evidence for transmission via airborne droplets or contaminated surfaces.
Clinical manifestations vary: Many individuals experience subclinical infection, identifiable only by the presence of antibodies to HSV in the blood.
Incubation: Ranges from several days to 2 weeks.

Symptoms: Vesicular lesions appear in the oral and perioral area (primarily gingiva and palate), often accompanied by systemic symptoms: fever, malaise, cervical lymphadenopathy.
The primary infection may resolve in 7-10 days, potentially leading to virus latency in the trigeminal ganglion.

Virulence factors during Latency: During latency, no free virus or major histocompatibility (MHC) antigens are present, resulting in no T-cell response.
Reactivation Triggers: Factors such as sunlight, cold, trauma, stress, and immunosuppression may reactivate the virus, leading to secondary infections characterized by similar vesiculoulcerative lesions.

Occurs mainly in children, with adults susceptible if naive to the virus.
By age 15, about half of the population is infected.
Primary Herpetic Symptoms:
- Vesicular eruptions that rupture to form ulcers.
- Systemic reactions include fever and malaise, followed by resolution without scarring.

Represents reactivation of latent HSV.
Most common in individuals who have previously infected, with prodromal symptoms often presenting as tingling before lesions develop.
Lesion Characteristics:
- Typically appear on vermilion, lips, and gingiva, healing within 1-2 weeks.
- The recurrence rate may vary greatly and decreases as individuals age.

Secondary herpes can result in severe manifestations in immunocompromised individuals, featuring chronic and destructive lesions.
Co-infection with cytomegalovirus (CMV) may occur in HIV patients, but its pathogenesis remains unclear.

Many differential diagnoses exist including:
- Streptococcal Pharyngitis: No vesicular stage, lesions localized.
- Erythema Multiforme: Larger ulcers, less likely to affect gingiva.
- Acute Necrotizing Ulcerative Gingivitis (ANUG): Mainly affects young adults with significant oral malodor.
- Aphthous Stomatitis: Non-keratinized mucosa and lesions differ clinically.

Timing: The effectiveness of treatment relies on prompt initiation (within 48 hours).
Acyclovir and Analogs:
- Acyclovir is converted by viral enzymes to inhibit viral DNA polymerase, sparing host cellular processes.
- Dosage: Systemic acyclovir can be administered in doses of 200-400 mg five times daily.
- Topical Treatment: A 5% acyclovir ointment has limited efficacy.
Supportive Measures: Fluids, rest, analgesics, and antipyretics are integral parts of the treatment regimen for herpes simplex infections, particularly for systemic primary infections.

Asymptomatic shedding of virus can occur in healthy adults. The risk of transmission from shedding has not been definitively established, though it is presumed low.
Previous associations with HSV and carcinoma have largely been refuted, attributing little or no etiological significance to HSV in oral cancers.

The vast majority of HSV infections are manageable with early intervention and support, especially in immunocompromised populations who may endure more severe consequences.